Orchid Pharma Limited announces an acquisition

The approved final share swap ratio for the amalgamation of Dhanuka Laboratories Limited into Orchid Pharma Limited is 161 fully paid-up equity shares of Orchid Pharma (face value Rs 10 each) for every 5 fully paid-up equity shares of Dhanuka Laboratories (face value Rs 100 each, prior to sub-division) ^[1]. This corporate action results in a derived 291.43% increase in Orchid Pharma's total paid-up equity capital.

Key Evidence and Allotment Metrics

• Swap Ratio Structure: 161 equity shares of Orchid Pharma (Rs 10 face value) issued for every 5 equity shares of Dhanuka Laboratories (Rs 100 face value, subsequently sub-divided to Rs 10) ^[1].
• Shares Allotted: Orchid Pharma's Board approved the issuance and allotment of 44,586,052 equity shares of Rs 10 each to eligible shareholders of Dhanuka Laboratories as of the record date of July 23, 2026 ^[2].
• Post-Allotment Capital: Following the allotment and cancellation of cross-holdings, Orchid Pharma's total paid-up share capital increased to Rs 59,88,52,000, structured across 5,98,85,200 equity shares of Rs 10 each ^[2].
• Pre-Allotment Base (Derived): Derived pre-arm base of 15,299,148 shares, calculated by subtracting the newly allotted shares (44,586,052) ^[2] from the post-allotment total (5,98,85,200) ^[2].
• Capital Expansion (Derived): The 44,586,052 newly issued shares ^[2] represent a 291.43% increase over the pre-allotment equity base of 15,299,148 shares ^[2].

Implication

The substantial equity dilution—more than tripling the share count—reflects the full absorption of Dhanuka Laboratories' business operations into Orchid Pharma under the NCLT-sanctioned scheme, consolidating the promoter group's control block while expanding the combined entity's capital base to support projected revenue and EBITDA scale ^[1], ^[3], ^[4].

Financial Contribution & Strategic Integration

The full pro-forma financial statement tables submitted in the Scheme of Arrangement filing were not reported in available disclosures. However, credit rating disclosures and post-approval merger announcements detail the financial profile of Dhanuka Laboratories Limited (DLL) and the post-merger expectations for Orchid Pharma Limited (OPL):

• Incremental Revenue Contribution: DLL contributes standalone annual revenue of Rs 500 Crores to Rs 600 Crores ^[5]. Relative to Orchid Pharma's FY26 consolidated revenue of Rs 811.33 Crores ^[6], DLL adds approximately 61.6% to 73.9% in top-line scale.
• Incremental EBITDA Contribution: DLL operates at a PBILDT/EBITDA margin of ~7.00% to 8.00% ^[5], providing an estimated incremental EBITDA contribution of Rs 35 Crores to Rs 48 Crores (derived from reported revenue and margin ranges).
• Combined Target Entity: Following final NCLT approval for the scheme of amalgamation, management targets a combined entity revenue of Rs 1,400 Crores to Rs 1,500 Crores and an EBITDA of Rs 200 Crores to Rs 250 Crores ^[7] (up from OPL's FY26 consolidated EBITDA of Rs 76.31 Crores ^[8]).
• Impact on API Manufacturing Capacity: DLL expands Orchid’s active pharmaceutical ingredient (API) manufacturing base by integrating DLL’s established cephalosporin API manufacturing facilities, which primarily serve non-regulated and semi-regulated markets ^[5]. This complements Orchid Pharma’s existing API regulatory footprint of 48 cumulative United States Drug Master File (US DMF) filings ^[5].

---

Pro-Forma & Financial Profile Comparison

`Notes:` † Derived from reported lower/upper range boundaries.

---

Key Analytical Implications

• Margin Trajectory & Dilution: DLL’s lower operating profitability (~7.00% to 8.00% PBILDT margin ^[5]) moderates Orchid Pharma's consolidated profitability profile ^[5], which historically reached 17.20% in FY24 ^[9]. However, the targeted merged EBITDA margin of ~14.30% to 16.70% ^[7] relies on intra-group balance adjustments, operational synergies, and downstream project rollouts ^[5].
• Market & Product Diversification: The merger transitions Orchid Pharma from a predominantly regulated-market API entity into a broader supplier spanning non-regulated, semi-regulated, and regulated markets ^[5].
• Vertical Integration & Capital Structure: The amalgamation eliminates intra-group balances and supports capital deployment toward key strategic initiatives, including the 7-ACA project and downstream expansion at the Alathur facility ^[5].

---

Disclosure Limits

• Specific Tonnage/Volume Capacity: Exact quantitative additions to API production capacity (such as metric tons per annum or reactor volume) from the Scheme of Arrangement schedules were not reported in available sources.
• Detailed Pro-Forma Financial Statements: The line-item pro-forma balance sheet and income statement submitted to the NCLT were not accessible in cited filings; figures reflect CARE Ratings releases and NCLT approval disclosures ^[7], ^[5].

The valuation implied by the share swap ratio for Dhanuka Laboratories cannot be directly equated to a standalone EV/EBITDA multiple from the retrieved disclosures, while Orchid Pharma trades at an EV/EBITDA multiple of approximately 45.02x ^[10]. Furthermore, the exact net percentage change in the promoter group's aggregate shareholding following the issuance is not explicitly quantified in the available filings or news context.

Share Swap Ratio and Implied Valuation Context

• Swap Terms: Under the Scheme of Amalgamation sanctioned by the NCLT with an appointed date of April 1, 2024, 161 fully paid-up equity shares of Orchid Pharma (face value Rs 10) are to be issued for every 5 equity shares of Dhanuka Laboratories (face value Rs 100, subsequently sub-divided to Rs 10) ^[1].
• Combined Projections: The amalgamated entity is projected to achieve annual revenue of Rs 1,400–1,500 Crores and EBITDA of Rs 200–250 Crores ^[1].
• Valuation Disclosure Gap: An explicit enterprise value or implied EV/EBITDA multiple for Dhanuka Laboratories derived from the swap ratio is not separately reported in the primary disclosures, making a direct multiple comparison unquantifiable from public records alone.

Orchid Pharma Trading Multiples

• EV/EBITDA: Orchid Pharma trades at an Enterprise Value to EBITDA multiple of 45.02x, based on an enterprise value of approximately Rs 3,010 Crores (Rs 30.10B) ^[10].
• Earnings Base: Orchid Pharma's reported TTM consolidated EBITDA stood at Rs 76.31 Crores for Q4 FY26 ^[11], while standalone TTM EBITDA was Rs 100.58 Crores ^[12]. Trailing P/E ratios range from 110.61x ^[13] to 150.55x ^[10].

Promoter Group Shareholding Impact

• Pre-Merger Holding: Dhanuka Laboratories Limited holds 69.84% (35,419,957 shares) of Orchid Pharma as the primary promoter entity ^[14].
• Issuance Mechanics: Because Dhanuka Laboratories is the amalgamating company merging into Orchid Pharma, new shares are issued to Dhanuka Laboratories' underlying shareholders in exchange for their holdings ^[1], effectively replacing corporate promoter holding with direct individual/holding-company promoter ownership.
• Net Change Disclosure Gap: The exact net percentage point change in the promoter group's aggregate shareholding post-issuance is not disclosed in the retrieved equity filings or share allotment updates.